Taufon ch. drops of 4% fl.-dropper 10ml No. 1

Release form, composition and packaging

Eye drops are transparent, colorless.

1 ml

taurine

40 mg

methylhydroxybenzoate 1 mg, sodium hydroxide solution 1 M to pH 5.0 - 6.5, water d / and up to 1 ml.

1.5 ml - dropper tube (1) - cardboard packs.

1.5 ml - dropper tube (2) - cardboard packs.

1.5 ml - dropper tube (4) - cardboard packs.

1.5 ml - dropper tube (5) - cardboard packs.

1.5 ml - tube-droppers (10) - cardboard packs.

2 ml - dropper tube (1) - cardboard packs.

2 ml - dropper tube (2) - cardboard packs.

2 ml - dropper tube (4) - cardboard packs.

2 ml - dropper tube (5) - cardboard packs.

2 ml - dropper tube (10) - cardboard packs.

5 ml - dropper tube (1) - cardboard packs.

5 ml - dropper tube (2) - cardboard packs.

5 ml - dropper tube (4) - cardboard packs.

5 ml - dropper tube (5) - cardboard packs.

5 ml - dropper tube (10) - cardboard packs.

5 ml - polymer bottle-droppers (1) - cardboard packs.

5 ml - polymer bottle-droppers (2) - cardboard packs.

10 ml - polymer bottle-droppers (1) - cardboard packs.

10 ml - polymer bottle-droppers (2) - cardboard packs.

5 ml - bottles (1) - cardboard packs.

5 ml - bottles (5) - contoured cell packs (1) - cardboard packs.

pharmachologic effect

A sulfur-containing amino acid formed in the body during the conversion of cysteine.

Promotes the improvement of energy processes.

Stimulates reparative and regenerative processes in diseases of a dystrophic nature and / or diseases accompanied by a sharp violation of the metabolism of eye tissues.

Promotes the normalization of the functions of cell membranes, activation of energy metabolic processes. ''

Indications for use

For oral administration: cardiovascular failure of various etiologies, intoxication with cardiac glycosides, type 1 and type 2 diabetes mellitus.

For parenteral use: as part of combined drugs, cardiovascular failure (of various etiologies), intoxication with cardiac glycosides.

For use in ophthalmology: degenerative lesions of the retina, incl.

hereditary tapetoretinal abiotrophy, corneal dystrophy, cataract (senile, diabetic, traumatic, radiation), as well as corneal trauma (as a stimulator of reparative processes).

Contraindications for use

Hypersensitivity to taurine.

Dosage regimen

The dosage regimen depends on the indications and the dosage form used.

Side effect

Possibly: allergic reactions.

Special instructions There is evidence of the effectiveness of taurine as a means of reducing intraocular pressure in patients with glaucoma.

Name ENG

TAUFONE

Clinical and pharmacological group

A drug that stimulates regeneration processes for local use in ophthalmology

ATX code

Other drugs for treating eye conditions

Dosage

4% x 10ml

Structure

1 ml of solution contains: Active ingredients: taurine - 40 mg.

Excipients: methylhydroxybenzoate 1 mg, sodium hydroxide solution 1 M to pH 5.0 - 6.5, water d / and up to 1 ml.

Indications

The drug is prescribed for adults with: corneal dystrophies

senile, traumatic, radiation and other types of cataracts

corneal injuries (as a stimulator of reparative processes).

INN / Active ingredient

taurine

Contraindications

hypersensitivity to taurine

Storage conditions and periods

In a dark place, at a temperature not exceeding 15 degrees

vials and dropper bottles - no higher than 25 degrees.

Shelf life: 2 years (dropper tubes), 3 years (dropper bottles), 4 years (bottles), 1 month after opening

Specifications

Category

Cataract

Scope of the medicinal product

Eyes

Release form

Drops

Manufacturer country

Russia

Package quantity, pcs

one

Way of introduction

Into the conjunctival sac

Vacation conditions

Without recipe

Shelf life after opening

1 month

Volume, ml.

10 ml

Brand name

OTCPharm

The amount of the dosage form in the primary package

10 ml

Primary packaging type

Dropper bottle

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Metabolic agent

Anatomical and therapeutic characteristics

S01XA Other preparations for the treatment of eye diseases

Dosage form

Eye drops

Expiration date in days

1095

Dosage (volume) of the substance in the preparation

40 mg

Package weight, g

twenty

Mode of application

:

In case of cataract, it is prescribed in the form of instillations, 1-2 drops 2-4 times a day for 3 months.

The course is repeated at monthly intervals.

For injuries and dystrophic diseases of the cornea, it is used in the same doses for 1 month.

For the treatment of tapetoretinal abiotrophies and other degenerative diseases of the retina, for penetrating wounds of the cornea, 0.3 ml of a 4% solution is injected under the conjunctiva once a day for 10 days.

The course of treatment is repeated after 6-8 months.